New drug cocktail aims to stall rare gut tumors
NCT ID NCT07165886
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests whether adding a new form of sirolimus to a standard hormone-blocking drug (octreotide) can better control advanced neuroendocrine tumors of the stomach, intestines, or pancreas. About 298 adults with tumors that cannot be removed by surgery will receive the combination. The goal is to slow cancer growth and improve outcomes, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.